The fed­er­al gov­ern­ment has on­ly sent four ship­ments of Mer­ck’s Covid-19 an­tivi­ral mol­nupi­ravir (about 400,000 cours­es in each ship­ment) na­tion­wide, and al­ready HHS is re­port­ing … ...

Amerisource­Ber­gen earned a whop­ping $60.1 bil­lion last quar­ter, thanks in part to its dis­tri­b­u­tion of gov­ern­ment-owned Covid treat­ments. Now it’s time to rein­vest some of … ...

(This sto­ry is from our new Health Tech newslet­ter. If you’d like to sign up, just click here.) ...

Alex Gorsky, the CEO whose nine-year tenure at J&J was marred by law­suits over the com­pa­ny’s talc ba­by pow­der and opi­oids, will ...

When Pres­i­dent Joe Biden’s bud­get comes out on Thurs­day, ex­pect to see a big, po­ten­tial­ly mul­ti-bil­lion-dol­lar pro­pos­al to re­al­ly take a crack at cur­ing more … ...

PARIS — Last fall De­ci­phera suf­fered through a dis­as­trous set­back $DCPH with its lead drug, Qin­lock, which had been ap­proved as a fourth-line ther ...

Just a few days af­ter pric­ing a $150 mil­lion pub­lic of­fer­ing, Io­vance has now closed with 15% more raised, thanks to … ...

In a sur­prise U-turn, the Biden ad­min­is­tra­tion said Wednes­day that it will sup­port a pro­pos­al at the World Trade Or­ga­ni­za­tion to tem­porar­i­ly waive in­tel­lec­tu­al prop­er­ty … ...

Af­ter Pfiz­er and BioN­Tech scored the FDA’s emer­gency use au­tho­riza­tion for their mR­NA-based Covid-19 shot late last week, hopes are high that one or … ...

A bill that re­quires the Di­rec­tor of Na­tion­al In­tel­li­gence to de­clas­si­fy new in­for­ma­tion on the ori­gins of Covid-19 passed the House … ...

Months af­ter earn­ing its first ap­proval, Idor­sia is back with a Phase III win for a dif­fer­ent, J&J-part­nered drug.

No­va­cyt made a cash of­fer for mol­e­c­u­lar di­ag­nos­tics and screen­ing so­lu­tions com­pa­ny Your­gene Health as it ad­justs from a ma­jor drop in rev­enue due to … ...